Coherus Oncology (CHRS) Income from Non-Controlling Interests (2014 - 2018)
Coherus Oncology (CHRS) posted Income from Non-Controlling Interests of -$18000.0 for Q3 2018, up 61.7% sequentially from -$47000.0 in Q2 2018, and down 350.0% YoY from $7200.0 in Q3 2017.
Coherus Oncology (CHRS) Income from Non-Controlling Interests (2014 - 2018) Analysis & Trends
Coherus Oncology has reported Income from Non-Controlling Interests for 5 years, with the latest figure at -$18000.0 in Q3 2018.
- Quarterly Income from Non-Controlling Interests fell 350.0% year-over-year to -$18000.0 in Q3 2018, while the trailing twelve-month figure through Jun 2019 was -$18000.0 (down 131.03% YoY) and the FY2018 annual result came in at -$70000.0, changed N/A from the prior year.
- Income from Non-Controlling Interests advanced to -$18000.0 in Q3 2018 per CHRS's latest filing, from -$47000.0 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $155000.0 in Q4 2014 and troughed at -$224000.0 in Q2 2015.
- A 5-year average of -$66611.1 and a median of -$56500.0 in 2017 frame the typical range for Income from Non-Controlling Interests.
- The sharpest annual moves came in 2017 and 2018: Income from Non-Controlling Interests jumped 595.65% in 2017, then slumped 350.0% in 2018.
- Over 5 years, Income from Non-Controlling Interests stood at $155000.0 in 2014, then slumped by 221.94% to -$189000.0 in 2015, then surged by 87.83% to -$23000.0 in 2016, then surged by 595.65% to $114000.0 in 2017, then slumped by 115.79% to -$18000.0 in 2018.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered -$18000.0, -$47000.0, and -$5000.0 for Q3 2018, Q2 2018, and Q1 2018 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | -18,000.00 |
| Jun 30, 2018 | -47,000.00 |
| Mar 31, 2018 | -5,000.00 |
| Dec 31, 2017 | 114,000.00 |
| Sep 30, 2017 | -4,000.00 |
| Jun 30, 2017 | -66,000.00 |
| Mar 31, 2017 | -44,000.00 |
| Dec 31, 2016 | -23,000.00 |
| Sep 30, 2016 | -95,000.00 |
| Jun 30, 2016 | -183,000.00 |
| Mar 31, 2016 | -150,000.00 |
| Dec 31, 2015 | -189,000.00 |
| Sep 30, 2015 | -151,000.00 |
| Jun 30, 2015 | -224,000.00 |
| Mar 31, 2015 | -114,000.00 |
| Dec 31, 2014 | 155,000.00 |
| Sep 30, 2014 | -42,000.00 |
| Jun 30, 2014 | -113,000.00 |